Keywords
atrial fibrillation, radiofrequency ablation, recurrence prediction, antiarrhythmic therapy.
How to Cite
Karnialiuk, A., Mrochek, A., Karnialiuk, I., & Rabtsevich, V. (2016). Determination of antiarrhythmic therapy duration in patients with paroxysmal atrial fibrillation after radiofrequency pulmonary veins isolation on the results of preoperative assessment. The Practitioner, (4), 38-41. Retrieved from https://plr.com.ua/index.php/journal/article/view/178
Abstract
In patients with paroxysmal non-valvular atrial fibrillation (AF) preoperative elevation of interleukin‑6 (IL‑6) above 1.77 μmol/L increases the risk of AF recurrence within 3-6 months after radiofrequency pulmonary veins isolation (RF PVI) (OR 7 [0.61; 79.88]). Daily maximum heart rate above 120 beats per minute on ECG monitoring before RF PVI is associated with an increased likelihood of AF recurrence (OR 4,95 [0.86; 28.64]). Antiarrhythmic drug therapy during 6 months is recommended for patients with increased risk of AF recurrence.
References
1. Rhythm control versus rate control for atrial fibrillation and heart failure / D. Roy, M. Talajic, S. Nattel [et al.] // N. Engl. J. Med. — 2008. — Vol. 358. — P. 2667-2677.
2. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study / J. Carlsson,
S. Miketic, J. Windeler [et al.] // J. Am. Coll. Cardiol. — 2003. — Vol. 41. — P. 1690-1696.
3. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study / J.S. Steinberg, A. Sadaniantz,
J. Kron [et al.] // Circulation. — 2004. — Vol. 109. — P. 1973-1980.
4. Rate control vs. rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT
CAFE) Study / G. Opolski, A. Torbicki, D.A. Kosior [et al.] // Chest. — 2004. — Vol. 126. — P. 476-486.
5. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study /
V.E. Hagens, A.V. Ranchor, S.E. Van [et al.] // J. Am. Coll. Cardiol. — 2004. — Vol. 43. — P. 241-247.
6. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural
techniques, patient management and follow-up, definitions, endpoints, and research trial design / H. Calkins, K.H. Kuck, R. Cappato [et al.] // Europace. —
2012. — Vol. 14. — P. 528-606.
7. Efficacy of antiarrhythmic drugs short–term use after catheter ablation for atrial fibrillation (EAST–AF) trial / K. Kaitani, K. Inoue, A. Kobori [et al.] // Eur.
Heart J. — 2016. — Vol. 37. — P. 610-618.
8. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo–controlled
study (AMIO-CAT trial) / S. Darkner, X. Chen, J. Hansen [et al.] // Eur. Heart J. — 2014. — Vol. 35. — P. 3356-3364.
9. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) /
A.J. Camm, P. Kirchhof, G.Y. Lip [et al.] // Eur. Heart J. — 2010. — Vol. 31. — P. 2369-2429.
10. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta–analysis / A.N. Ganesan, N.J. Shipp, A.G. Brooks [et al.] // J. Am.
Heart Assoc. — 2013. — Vol. 2. — ID e004549.
11. Meta-analysis of association between C–reactive protein and immediate success of electrical cardioversion in persistent atrial fibrillation / T. Liu, L. Li,
P. Korantzopoulos [et al.] // Am. J. Cardiol. — 2008. — Vol. 101. — Р. 1749-1752.
12. Prognostic significance of raised plasma levels of interleukin‑6 and C-reactive protein in atrial fibrillation / D.S. Conway, P. Buggins, E. Hughes, G.Y. Lip // Am.
Heart J. — 2004. — Vol. 148. — P. 462-466.
13. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation / E. Hatzinikolaou-Kotsakou, D. Tziakas, A. Hotidis [et al.] // Am.
J. Cardiol. — Vol. 97. — P. 659-661.
14. C-reactive protein and atrial fibrillation: «Evidence for the presence of inflammation in the perpetuation of the arrhythmia» / M. Acevedo, R. Corbalán,
S. Braun [et al.] // Int. J. Cardiol. — 2006. — Vol. 108. — P. 326-331.
2. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study / J. Carlsson,
S. Miketic, J. Windeler [et al.] // J. Am. Coll. Cardiol. — 2003. — Vol. 41. — P. 1690-1696.
3. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study / J.S. Steinberg, A. Sadaniantz,
J. Kron [et al.] // Circulation. — 2004. — Vol. 109. — P. 1973-1980.
4. Rate control vs. rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT
CAFE) Study / G. Opolski, A. Torbicki, D.A. Kosior [et al.] // Chest. — 2004. — Vol. 126. — P. 476-486.
5. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study /
V.E. Hagens, A.V. Ranchor, S.E. Van [et al.] // J. Am. Coll. Cardiol. — 2004. — Vol. 43. — P. 241-247.
6. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural
techniques, patient management and follow-up, definitions, endpoints, and research trial design / H. Calkins, K.H. Kuck, R. Cappato [et al.] // Europace. —
2012. — Vol. 14. — P. 528-606.
7. Efficacy of antiarrhythmic drugs short–term use after catheter ablation for atrial fibrillation (EAST–AF) trial / K. Kaitani, K. Inoue, A. Kobori [et al.] // Eur.
Heart J. — 2016. — Vol. 37. — P. 610-618.
8. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo–controlled
study (AMIO-CAT trial) / S. Darkner, X. Chen, J. Hansen [et al.] // Eur. Heart J. — 2014. — Vol. 35. — P. 3356-3364.
9. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) /
A.J. Camm, P. Kirchhof, G.Y. Lip [et al.] // Eur. Heart J. — 2010. — Vol. 31. — P. 2369-2429.
10. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta–analysis / A.N. Ganesan, N.J. Shipp, A.G. Brooks [et al.] // J. Am.
Heart Assoc. — 2013. — Vol. 2. — ID e004549.
11. Meta-analysis of association between C–reactive protein and immediate success of electrical cardioversion in persistent atrial fibrillation / T. Liu, L. Li,
P. Korantzopoulos [et al.] // Am. J. Cardiol. — 2008. — Vol. 101. — Р. 1749-1752.
12. Prognostic significance of raised plasma levels of interleukin‑6 and C-reactive protein in atrial fibrillation / D.S. Conway, P. Buggins, E. Hughes, G.Y. Lip // Am.
Heart J. — 2004. — Vol. 148. — P. 462-466.
13. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation / E. Hatzinikolaou-Kotsakou, D. Tziakas, A. Hotidis [et al.] // Am.
J. Cardiol. — Vol. 97. — P. 659-661.
14. C-reactive protein and atrial fibrillation: «Evidence for the presence of inflammation in the perpetuation of the arrhythmia» / M. Acevedo, R. Corbalán,
S. Braun [et al.] // Int. J. Cardiol. — 2006. — Vol. 108. — P. 326-331.
Downloads
Download data is not yet available.